Merck & (MRK) stock
Last close $133.72 on 2026-11-20 (+0.69%) · Sector: Healthcare
Merck & Co. is a large American drugmaker based in Rahway, New Jersey, that develops and sells prescription medicines and vaccines for areas such as cancer, infections, and heart and animal health. It makes most of its money by selling these medicines to hospitals, pharmacies, and health systems around the world, and it reinvests a large share of that money into research to find new drugs.
Merck's revenue is growing slowly, at 4.9% over the past year, and its latest quarter was profitable with a net income of $5.1 billion. Over the past year the stock returned 33.2% while the S&P 500 returned 3.2%, so it has beaten the broader market. The stock is currently 14.8% below its 52-week high and 8.0% below its 50-day average, and insiders sold $29.3 million of stock in the last 90 days with no insider buys. After its last four earnings reports, the stock rose the next day three times and fell once.
Key numbers
- Market cap: $331.4B
- Revenue (last 12 months): $67.39B
- Revenue growth: +4.9%
- Gross margin: 71.7%
- P/E: 137.9
- P/S: 4.9
- Debt to equity: 1.11
- Current ratio: 1.35
Quality score
Overall 20/100 · growth 34 · profitability None · financial health 26 · value 0
Performance and risk
1-year return +33.2% vs S&P 500 +3.1% · volatility 30.2% (S&P 500 14.2%) · largest drop -15.1% · beta 0.24
Stock move the day after earnings
- 2026-02-03: +2.2%
- 2026-04-30: -1.6%
- 2026-08-04: +0.2%
- 2026-10-29: +3.8%
Congress trades (90 days)
1 buys, 0 sells
Insider trades (12 months)
Bought $0.0M · sold $79.3M
MRK stock research · MRK options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.